Back to search

Aristotle University Of Thessaloniki (AUTH)

Μοριακή μελέτη της απόπτωσης των λευχαιμικών κυττάρων σε ηλικιωμένους ασθενείς με οξεία μυελογενή λευχαιμία

Abstract

dc:description

Acute Myeloid Leukemia (AML) is a complex disease with considerabe phenotypical and genotypical heterogeneity. More than 50% of patients with AM are over 60 years-of-age. Age is one of the most important adverse prognostic factors and the optimal therapy of AML in elderly patients remains a controversial issue. Several biologic features of AML differ between older and younger individuals. Older patients often express multidrug resistant phenotype and cytogenic abnormalities, which may be responsible in large part for the poor outcomes observed in older-aged subgroups. Traditional cytotoxic chemotherapy is associated with a low complete response rate and a high treatment-related mortality in older patients, which explains in large part the poorer outcomes observed in individuals over 60 years of age. For that reason, treatment for the elderly AML patients should be based on biologic and prognostic factors. Research into the pathophysiology of AML has revealed and abundance of intracellular signaling events that govern proliferation, differentiation, self-renewal and apoptosis. Apoptosis, or programmed cell death, is the mechanism which controls the balance between cell death and cell proliferation and acts to preserve homeostasis in tissues. Survivin is a member of the inhibitor of apoptosis protein (IAP) family and is characterized as a bi-functional protein, implicated in both regulation of cell division and inhibition of apoptosis. Unlike othe IAPs, surviving is expressed primarily in fetal but not adult tissues and its expression is aberrantly enhanced in most cancers. Survivin takes part in cancer progression and resistance to therapy, in diverse tumour types and haematologic malignancies. Therefore, it has been proposed that surviving could be used as a prognostic marker or a cancer therapeutic target, especially in cases where conventional cytotoxic chemotherapy is associated with serious adverse effects and cannot be well tolerated. A surviving-antisense approach would be expected to carry limited toxicity for normal cells and therefore, it could be more tolerable by elderly patients. In this study, surviving expression was examined in elderly AML patients at diagnosis and in complete remission after chemotherapy and was correlated with the expression in control individuals. The semi-quantitative evaluation of the mRNA expression was performed, in both bone marrow and peripheral blood cells, with the use of the Real-Time RT-PCR method, while serum protein levels were estimated with the use of immunoassay technique ELISA. Real-Time RT-PCR is an extremely sensitive, precise and accurate method, which is used for the quantitative determination of mRNA levels, even when a genes’s expression is rather low. Futhermore, the expression of surviving, in both mRNA and protein level was correlated with well-known prognostic factors for AML (such as age, FAB classification, karyotype and type of leukemia) and the response to chemotherapy. In the present study, survivin expression was detected in all elderly AML patients at diagnosis and in complete remission, in both protein and mRNA level. Moreover, survivin mRNA levels were found in bone marrow cells of all control individuals, while Real-Time RT-PCR method revealed low mRNA expression levels in peripheral blood cells of the control individuals. In bone marrow cells, mRNA expression was significantly lower, compared to control individuals, while in peripheral blood cells, both mRNA and protein levels were significantly higher. In patients in complete remission, both mRNA and protein levels were similar and not significantly different from the levels in control group. High mRNA expression levels in bone marrow cells were significantly correlated with unfavourable karyotype, unfavourable type of FAB classification and secondary AML, while high mRNA levels in peripheral blood cells were significantly correlated with unfavourable karyotype and failure to achieve complete remission. Finally, high serum protein levels were significantly correlated with failure to response in chemotherapy. From the present study, it is not clear whether surviving could be used as a potential molecular target for the therapeutic approach of AML. However, it is shown that the study of surviving expression, primarily in peripheral blood cells, could be used as an unfavourable prognostic marker, a marker of resistance in chemotherapeutic drugs or a minimal residual disease indicator.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2008

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tsiga, Alexandra
  • Τσίγκα, Αλεξάνδρα

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/19487

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tsiga, Alexandra; Τσίγκα, Αλεξάνδρα. Μοριακή μελέτη της απόπτωσης των λευχαιμικών κυττάρων σε ηλικιωμένους ασθενείς με οξεία μυελογενή λευχαιμία. Aristotle University Of Thessaloniki (AUTH), 2008. http://hdl.handle.net/10442/hedi/19487